| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 361 | 2024 | 2979 | 41.750 |
Why?
|
| Azacitidine | 138 | 2024 | 1149 | 16.970 |
Why?
|
| Leukemia, Myeloid, Acute | 317 | 2024 | 6915 | 16.230 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 48 | 2024 | 426 | 15.060 |
Why?
|
| Antimetabolites, Antineoplastic | 65 | 2023 | 1299 | 7.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 225 | 2024 | 15862 | 6.180 |
Why?
|
| DNA Methylation | 87 | 2024 | 2669 | 6.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 102 | 2023 | 2527 | 5.580 |
Why?
|
| Cytarabine | 93 | 2023 | 1973 | 5.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 86 | 2024 | 2796 | 5.330 |
Why?
|
| Aged, 80 and over | 355 | 2024 | 29902 | 4.750 |
Why?
|
| Aged | 543 | 2024 | 70117 | 4.600 |
Why?
|
| Histone Deacetylase Inhibitors | 29 | 2019 | 612 | 4.580 |
Why?
|
| Mutation | 135 | 2023 | 15179 | 4.240 |
Why?
|
| Antineoplastic Agents | 154 | 2023 | 14289 | 4.210 |
Why?
|
| Middle Aged | 569 | 2024 | 86204 | 4.160 |
Why?
|
| Humans | 905 | 2024 | 261506 | 4.050 |
Why?
|
| Myeloproliferative Disorders | 28 | 2024 | 767 | 3.950 |
Why?
|
| Prognosis | 247 | 2024 | 21713 | 3.880 |
Why?
|
| Leukemia | 36 | 2022 | 1635 | 3.870 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 27 | 2024 | 923 | 3.730 |
Why?
|
| Remission Induction | 124 | 2024 | 3569 | 3.510 |
Why?
|
| Adult | 477 | 2024 | 77950 | 3.480 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 37 | 2022 | 801 | 3.470 |
Why?
|
| Hematology | 8 | 2023 | 104 | 3.390 |
Why?
|
| Male | 522 | 2024 | 123000 | 3.350 |
Why?
|
| Bone Marrow | 60 | 2023 | 2358 | 3.210 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 11 | 2023 | 114 | 3.150 |
Why?
|
| Female | 512 | 2024 | 141928 | 3.010 |
Why?
|
| Treatment Outcome | 271 | 2024 | 32848 | 3.010 |
Why?
|
| Protein Kinase Inhibitors | 77 | 2023 | 4757 | 2.990 |
Why?
|
| Sulfonamides | 31 | 2024 | 1823 | 2.900 |
Why?
|
| Idarubicin | 32 | 2023 | 446 | 2.770 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 64 | 2023 | 6550 | 2.700 |
Why?
|
| Chromosome Aberrations | 48 | 2023 | 1960 | 2.690 |
Why?
|
| Philadelphia Chromosome | 41 | 2023 | 793 | 2.670 |
Why?
|
| Pyrimidines | 84 | 2020 | 3518 | 2.590 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 30 | 2023 | 505 | 2.550 |
Why?
|
| Epigenesis, Genetic | 24 | 2019 | 1399 | 2.490 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 5 | 2022 | 113 | 2.430 |
Why?
|
| Hematinics | 8 | 2023 | 109 | 2.420 |
Why?
|
| Blast Crisis | 25 | 2022 | 557 | 2.410 |
Why?
|
| Hematopoiesis | 16 | 2024 | 560 | 2.370 |
Why?
|
| Hydroxamic Acids | 15 | 2020 | 442 | 2.360 |
Why?
|
| Benzimidazoles | 9 | 2022 | 428 | 2.340 |
Why?
|
| Anemia, Sideroblastic | 7 | 2022 | 58 | 2.320 |
Why?
|
| Survival Rate | 118 | 2023 | 12221 | 2.290 |
Why?
|
| Piperazines | 65 | 2021 | 2101 | 2.230 |
Why?
|
| Disease-Free Survival | 110 | 2023 | 10001 | 2.200 |
Why?
|
| Leukemia, Myeloid | 28 | 2019 | 941 | 2.170 |
Why?
|
| RNA Splicing Factors | 15 | 2023 | 153 | 2.120 |
Why?
|
| Young Adult | 168 | 2023 | 21445 | 2.100 |
Why?
|
| Survival Analysis | 107 | 2021 | 9180 | 2.060 |
Why?
|
| Enzyme Inhibitors | 33 | 2021 | 1879 | 2.050 |
Why?
|
| Uridine | 4 | 2024 | 59 | 2.040 |
Why?
|
| Isocitrate Dehydrogenase | 14 | 2023 | 480 | 2.040 |
Why?
|
| Hematologic Neoplasms | 25 | 2022 | 1870 | 2.020 |
Why?
|
| Neoplasms, Second Primary | 21 | 2022 | 1350 | 2.010 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 4 | 2022 | 33 | 1.970 |
Why?
|
| Phosphoproteins | 13 | 2022 | 1152 | 1.930 |
Why?
|
| Tumor Suppressor Protein p53 | 27 | 2023 | 3552 | 1.920 |
Why?
|
| Neoplasm Proteins | 22 | 2021 | 3230 | 1.900 |
Why?
|
| Thrombocytosis | 6 | 2022 | 121 | 1.890 |
Why?
|
| Kaplan-Meier Estimate | 64 | 2021 | 6207 | 1.890 |
Why?
|
| Gene Expression Regulation, Leukemic | 16 | 2018 | 560 | 1.820 |
Why?
|
| Thrombocytopenia | 16 | 2023 | 846 | 1.810 |
Why?
|
| Benzamides | 69 | 2015 | 1832 | 1.780 |
Why?
|
| Immunologic Factors | 10 | 2021 | 649 | 1.760 |
Why?
|
| Leukemia, Promyelocytic, Acute | 16 | 2021 | 430 | 1.750 |
Why?
|
| Follow-Up Studies | 96 | 2023 | 14889 | 1.750 |
Why?
|
| Translocation, Genetic | 21 | 2023 | 1245 | 1.710 |
Why?
|
| Antibodies, Monoclonal | 31 | 2023 | 4367 | 1.670 |
Why?
|
| Adolescent | 178 | 2024 | 31252 | 1.670 |
Why?
|
| Salvage Therapy | 39 | 2023 | 2054 | 1.640 |
Why?
|
| Arabinonucleosides | 19 | 2021 | 437 | 1.640 |
Why?
|
| Cytogenetic Analysis | 28 | 2024 | 568 | 1.620 |
Why?
|
| Neutropenia | 13 | 2023 | 968 | 1.610 |
Why?
|
| Drug Administration Schedule | 64 | 2021 | 3472 | 1.600 |
Why?
|
| Biomarkers, Tumor | 38 | 2021 | 10331 | 1.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 33 | 2023 | 3251 | 1.580 |
Why?
|
| Thalidomide | 15 | 2022 | 569 | 1.580 |
Why?
|
| Valproic Acid | 10 | 2014 | 263 | 1.580 |
Why?
|
| Stem Cell Transplantation | 20 | 2023 | 1360 | 1.570 |
Why?
|
| Anemia | 16 | 2023 | 689 | 1.520 |
Why?
|
| Drug Resistance, Neoplasm | 49 | 2023 | 5178 | 1.470 |
Why?
|
| Recurrence | 70 | 2023 | 4758 | 1.460 |
Why?
|
| Risk | 24 | 2021 | 1972 | 1.460 |
Why?
|
| Cyclophosphamide | 38 | 2023 | 3001 | 1.440 |
Why?
|
| Nuclear Proteins | 24 | 2023 | 3343 | 1.440 |
Why?
|
| Hematopoietic Stem Cells | 15 | 2024 | 1242 | 1.400 |
Why?
|
| Janus Kinase 2 | 14 | 2020 | 679 | 1.370 |
Why?
|
| Imatinib Mesylate | 70 | 2019 | 1665 | 1.360 |
Why?
|
| Activin Receptors, Type II | 5 | 2023 | 38 | 1.360 |
Why?
|
| Adenine Nucleotides | 15 | 2017 | 351 | 1.360 |
Why?
|
| Immunoglobulin Fc Fragments | 5 | 2023 | 47 | 1.340 |
Why?
|
| Dose-Response Relationship, Drug | 53 | 2021 | 4938 | 1.320 |
Why?
|
| Pneumonia | 9 | 2024 | 751 | 1.320 |
Why?
|
| Fusion Proteins, bcr-abl | 34 | 2023 | 1094 | 1.310 |
Why?
|
| Retrospective Studies | 114 | 2024 | 37905 | 1.310 |
Why?
|
| Vincristine | 38 | 2023 | 1511 | 1.310 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 7 | 2021 | 118 | 1.290 |
Why?
|
| Erythrocyte Transfusion | 8 | 2021 | 212 | 1.270 |
Why?
|
| Administration, Oral | 21 | 2021 | 1544 | 1.250 |
Why?
|
| Antimetabolites | 2 | 2021 | 69 | 1.180 |
Why?
|
| Iron Chelating Agents | 7 | 2020 | 33 | 1.160 |
Why?
|
| Clonal Evolution | 7 | 2020 | 253 | 1.160 |
Why?
|
| Primary Myelofibrosis | 16 | 2022 | 831 | 1.160 |
Why?
|
| Neoplasms | 30 | 2024 | 15193 | 1.130 |
Why?
|
| Dioxygenases | 6 | 2022 | 159 | 1.110 |
Why?
|
| Disease Progression | 43 | 2021 | 6682 | 1.110 |
Why?
|
| Dexamethasone | 38 | 2023 | 1450 | 1.100 |
Why?
|
| Histones | 16 | 2018 | 1466 | 1.090 |
Why?
|
| Maximum Tolerated Dose | 26 | 2021 | 1290 | 1.090 |
Why?
|
| Chelation Therapy | 2 | 2017 | 5 | 1.090 |
Why?
|
| Gene Expression | 8 | 2018 | 3570 | 1.080 |
Why?
|
| Anemia, Aplastic | 5 | 2019 | 214 | 1.060 |
Why?
|
| Chromosome Inversion | 6 | 2023 | 182 | 1.060 |
Why?
|
| Clinical Trials as Topic | 31 | 2022 | 3719 | 1.050 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2023 | 482 | 1.040 |
Why?
|
| Toll-Like Receptors | 5 | 2020 | 174 | 1.040 |
Why?
|
| Cell Transformation, Neoplastic | 13 | 2021 | 2359 | 1.030 |
Why?
|
| Immunity, Innate | 5 | 2018 | 677 | 1.020 |
Why?
|
| Recombinant Fusion Proteins | 8 | 2022 | 1555 | 1.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 8 | 2022 | 234 | 1.000 |
Why?
|
| Chromosome Deletion | 13 | 2022 | 1005 | 0.990 |
Why?
|
| Dasatinib | 28 | 2023 | 862 | 0.990 |
Why?
|
| Neoplasm, Residual | 25 | 2023 | 1656 | 0.980 |
Why?
|
| Pyridazines | 10 | 2022 | 293 | 0.960 |
Why?
|
| Antigens, CD34 | 9 | 2019 | 593 | 0.950 |
Why?
|
| Erythropoiesis | 4 | 2023 | 74 | 0.950 |
Why?
|
| Induction Chemotherapy | 18 | 2023 | 669 | 0.940 |
Why?
|
| Hemoglobins | 8 | 2023 | 477 | 0.940 |
Why?
|
| Antibodies, Bispecific | 8 | 2023 | 246 | 0.940 |
Why?
|
| Risk Assessment | 32 | 2022 | 6869 | 0.920 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 19 | 2023 | 2390 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 19 | 2021 | 8873 | 0.910 |
Why?
|
| DNA-Binding Proteins | 13 | 2022 | 4821 | 0.910 |
Why?
|
| Transplantation, Homologous | 30 | 2023 | 2843 | 0.890 |
Why?
|
| Tandem Repeat Sequences | 9 | 2020 | 201 | 0.890 |
Why?
|
| Transcriptome | 5 | 2022 | 1859 | 0.890 |
Why?
|
| Doxorubicin | 31 | 2023 | 3005 | 0.890 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 2315 | 0.870 |
Why?
|
| Imidazoles | 12 | 2022 | 999 | 0.860 |
Why?
|
| Apoptosis | 25 | 2021 | 7591 | 0.860 |
Why?
|
| Pyrazoles | 9 | 2021 | 1471 | 0.850 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2024 | 10035 | 0.840 |
Why?
|
| Protein-Tyrosine Kinases | 34 | 2021 | 1756 | 0.840 |
Why?
|
| Sulfones | 3 | 2020 | 143 | 0.840 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2020 | 311 | 0.840 |
Why?
|
| Interferon Type I | 3 | 2021 | 250 | 0.830 |
Why?
|
| Myelopoiesis | 2 | 2021 | 31 | 0.820 |
Why?
|
| Glycine | 4 | 2021 | 289 | 0.810 |
Why?
|
| Acute Disease | 33 | 2022 | 2422 | 0.810 |
Why?
|
| Angiogenesis Inhibitors | 9 | 2021 | 1248 | 0.800 |
Why?
|
| Vidarabine | 19 | 2022 | 1341 | 0.780 |
Why?
|
| Age Factors | 33 | 2018 | 5377 | 0.780 |
Why?
|
| CpG Islands | 9 | 2013 | 633 | 0.770 |
Why?
|
| Risk Factors | 63 | 2023 | 17523 | 0.770 |
Why?
|
| Daunorubicin | 9 | 2023 | 301 | 0.760 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2022 | 2488 | 0.760 |
Why?
|
| Chromosomes, Human, Pair 5 | 9 | 2018 | 259 | 0.760 |
Why?
|
| Karyotyping | 24 | 2019 | 1022 | 0.760 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2021 | 173 | 0.760 |
Why?
|
| Neutrophils | 5 | 2022 | 835 | 0.750 |
Why?
|
| Promoter Regions, Genetic | 18 | 2015 | 3101 | 0.750 |
Why?
|
| High-Throughput Nucleotide Sequencing | 19 | 2022 | 2291 | 0.740 |
Why?
|
| Models, Biological | 10 | 2020 | 3254 | 0.740 |
Why?
|
| Karyotype | 14 | 2022 | 234 | 0.730 |
Why?
|
| Proportional Hazards Models | 33 | 2021 | 4988 | 0.730 |
Why?
|
| Gene Silencing | 11 | 2013 | 837 | 0.730 |
Why?
|
| Aminoglycosides | 18 | 2022 | 220 | 0.730 |
Why?
|
| Core Binding Factors | 7 | 2022 | 112 | 0.720 |
Why?
|
| Platelet Count | 14 | 2022 | 490 | 0.720 |
Why?
|
| Fatigue | 6 | 2019 | 1239 | 0.720 |
Why?
|
| DNA Mutational Analysis | 18 | 2018 | 2283 | 0.720 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 8 | 2024 | 197 | 0.710 |
Why?
|
| Histone Deacetylases | 5 | 2015 | 365 | 0.700 |
Why?
|
| HL-60 Cells | 8 | 2013 | 302 | 0.700 |
Why?
|
| Genes, ras | 6 | 2022 | 667 | 0.690 |
Why?
|
| Thiazoles | 17 | 2021 | 726 | 0.680 |
Why?
|
| Interferon-alpha | 15 | 2022 | 889 | 0.680 |
Why?
|
| ras Proteins | 8 | 2022 | 770 | 0.680 |
Why?
|
| Urea | 3 | 2015 | 290 | 0.680 |
Why?
|
| Oncogene Proteins, Fusion | 9 | 2021 | 755 | 0.680 |
Why?
|
| Graft vs Host Disease | 9 | 2021 | 2638 | 0.670 |
Why?
|
| Signal Transduction | 22 | 2022 | 11965 | 0.670 |
Why?
|
| GTP Phosphohydrolases | 5 | 2019 | 336 | 0.670 |
Why?
|
| Tretinoin | 14 | 2021 | 623 | 0.670 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2019 | 31 | 0.670 |
Why?
|
| Carbolines | 1 | 2018 | 27 | 0.670 |
Why?
|
| Phenylurea Compounds | 8 | 2021 | 580 | 0.670 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2021 | 1048 | 0.660 |
Why?
|
| Germ-Line Mutation | 8 | 2020 | 1046 | 0.660 |
Why?
|
| Repressor Proteins | 9 | 2023 | 1664 | 0.660 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 11 | 2022 | 749 | 0.660 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 479 | 0.660 |
Why?
|
| Up-Regulation | 4 | 2021 | 2450 | 0.650 |
Why?
|
| Pyrroles | 4 | 2010 | 576 | 0.650 |
Why?
|
| Blood Platelets | 3 | 2022 | 731 | 0.640 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2013 | 1064 | 0.640 |
Why?
|
| Flow Cytometry | 11 | 2019 | 3033 | 0.630 |
Why?
|
| Withholding Treatment | 2 | 2019 | 161 | 0.630 |
Why?
|
| Aminopyridines | 3 | 2021 | 212 | 0.630 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 184 | 0.630 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2018 | 119 | 0.620 |
Why?
|
| Combined Modality Therapy | 26 | 2021 | 8865 | 0.620 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 3 | 2014 | 72 | 0.620 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2016 | 160 | 0.610 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2021 | 305 | 0.610 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2013 | 726 | 0.610 |
Why?
|
| Autophagy | 4 | 2012 | 927 | 0.610 |
Why?
|
| Acetylation | 9 | 2016 | 508 | 0.610 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2013 | 1823 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 16 | 4 | 2021 | 254 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 11 | 6 | 2020 | 402 | 0.600 |
Why?
|
| Cladribine | 9 | 2023 | 233 | 0.600 |
Why?
|
| Anemia, Refractory | 2 | 2014 | 39 | 0.590 |
Why?
|
| Arsenicals | 10 | 2021 | 201 | 0.590 |
Why?
|
| Gene Expression Profiling | 10 | 2022 | 5159 | 0.590 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2016 | 18 | 0.580 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2023 | 447 | 0.580 |
Why?
|
| Bortezomib | 3 | 2020 | 543 | 0.580 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 334 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2022 | 5539 | 0.570 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2018 | 278 | 0.570 |
Why?
|
| Bone Marrow Examination | 2 | 2016 | 153 | 0.570 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 6 | 2021 | 217 | 0.570 |
Why?
|
| NF-kappa B | 4 | 2020 | 1549 | 0.570 |
Why?
|
| MicroRNAs | 9 | 2014 | 2947 | 0.560 |
Why?
|
| Cohort Studies | 32 | 2022 | 9244 | 0.560 |
Why?
|
| Leukemia, B-Cell | 2 | 2017 | 117 | 0.560 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 5 | 2008 | 64 | 0.560 |
Why?
|
| Indazoles | 2 | 2015 | 297 | 0.560 |
Why?
|
| Comorbidity | 7 | 2024 | 2352 | 0.550 |
Why?
|
| Histone-Lysine N-Methyltransferase | 8 | 2021 | 461 | 0.550 |
Why?
|
| Biomarkers | 14 | 2023 | 5047 | 0.550 |
Why?
|
| Cell Line, Tumor | 28 | 2022 | 14551 | 0.550 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2013 | 388 | 0.540 |
Why?
|
| RNA, Messenger | 17 | 2016 | 6150 | 0.540 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2014 | 155 | 0.530 |
Why?
|
| Severity of Illness Index | 9 | 2019 | 4320 | 0.530 |
Why?
|
| Prospective Studies | 26 | 2024 | 12873 | 0.530 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 16 | 2016 | 3639 | 0.520 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 8 | 2024 | 1331 | 0.510 |
Why?
|
| Isochromosomes | 3 | 2022 | 55 | 0.510 |
Why?
|
| Cell Cycle Proteins | 7 | 2023 | 2045 | 0.500 |
Why?
|
| Cell Proliferation | 21 | 2019 | 7226 | 0.500 |
Why?
|
| DNA Modification Methylases | 9 | 2014 | 172 | 0.500 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2022 | 1249 | 0.490 |
Why?
|
| Receptor, TIE-2 | 1 | 2014 | 82 | 0.490 |
Why?
|
| Stem Cell Niche | 1 | 2015 | 94 | 0.490 |
Why?
|
| Drugs, Investigational | 3 | 2014 | 135 | 0.490 |
Why?
|
| Polymerase Chain Reaction | 15 | 2021 | 3203 | 0.490 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 4 | 2022 | 245 | 0.490 |
Why?
|
| Congresses as Topic | 3 | 2021 | 298 | 0.490 |
Why?
|
| Leukemic Infiltration | 3 | 2018 | 72 | 0.480 |
Why?
|
| Immunophenotyping | 12 | 2021 | 1681 | 0.480 |
Why?
|
| Blood Transfusion | 6 | 2020 | 583 | 0.480 |
Why?
|
| Leukocyte Count | 12 | 2022 | 684 | 0.480 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 27 | 0.480 |
Why?
|
| Chromosomes, Human | 4 | 2017 | 295 | 0.480 |
Why?
|
| Methotrexate | 14 | 2023 | 999 | 0.470 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2013 | 249 | 0.470 |
Why?
|
| Hypertension | 1 | 2023 | 1503 | 0.460 |
Why?
|
| Multivariate Analysis | 24 | 2021 | 4298 | 0.460 |
Why?
|
| B-Lymphocytes | 5 | 2019 | 1294 | 0.460 |
Why?
|
| CTLA-4 Antigen | 5 | 2018 | 657 | 0.460 |
Why?
|
| Chromosome Mapping | 4 | 2022 | 1471 | 0.460 |
Why?
|
| Clone Cells | 3 | 2021 | 555 | 0.460 |
Why?
|
| Tumor Cells, Cultured | 12 | 2017 | 5395 | 0.460 |
Why?
|
| Indoles | 8 | 2017 | 1009 | 0.450 |
Why?
|
| Patient Care | 1 | 2014 | 149 | 0.450 |
Why?
|
| Oxides | 10 | 2021 | 211 | 0.450 |
Why?
|
| Propensity Score | 8 | 2022 | 750 | 0.450 |
Why?
|
| Hydrazines | 5 | 2021 | 208 | 0.450 |
Why?
|
| Membrane Proteins | 7 | 2019 | 2819 | 0.440 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2013 | 182 | 0.440 |
Why?
|
| Case-Control Studies | 16 | 2020 | 6100 | 0.440 |
Why?
|
| Receptors, Notch | 2 | 2013 | 383 | 0.440 |
Why?
|
| Iron Overload | 4 | 2020 | 35 | 0.440 |
Why?
|
| Immunosuppressive Agents | 7 | 2021 | 1375 | 0.430 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 6 | 2017 | 111 | 0.430 |
Why?
|
| Benzoates | 4 | 2021 | 136 | 0.430 |
Why?
|
| Patient Selection | 6 | 2018 | 2055 | 0.430 |
Why?
|
| Incidence | 16 | 2022 | 5673 | 0.420 |
Why?
|
| Medical Oncology | 5 | 2020 | 1423 | 0.420 |
Why?
|
| Drug Synergism | 7 | 2010 | 1313 | 0.420 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2013 | 709 | 0.420 |
Why?
|
| DNA, Neoplasm | 9 | 2018 | 1910 | 0.420 |
Why?
|
| Gene Expression Regulation | 8 | 2015 | 4053 | 0.420 |
Why?
|
| Bone Marrow Cells | 8 | 2018 | 943 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 9 | 5 | 2021 | 290 | 0.410 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2017 | 502 | 0.410 |
Why?
|
| Infusions, Intravenous | 19 | 2019 | 1382 | 0.410 |
Why?
|
| Monosomy | 3 | 2014 | 95 | 0.410 |
Why?
|
| B7-H1 Antigen | 3 | 2021 | 1022 | 0.410 |
Why?
|
| Neoplasm Staging | 19 | 2017 | 13658 | 0.410 |
Why?
|
| Gastrointestinal Diseases | 4 | 2020 | 589 | 0.410 |
Why?
|
| Molecular Targeted Therapy | 9 | 2021 | 2330 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 8 | 6 | 2017 | 317 | 0.390 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 5 | 2021 | 83 | 0.390 |
Why?
|
| Drug Combinations | 3 | 2024 | 621 | 0.390 |
Why?
|
| Patient Care Management | 1 | 2011 | 94 | 0.390 |
Why?
|
| Janus Kinase 1 | 3 | 2018 | 121 | 0.380 |
Why?
|
| Genome | 2 | 2022 | 672 | 0.380 |
Why?
|
| Lysine | 1 | 2013 | 422 | 0.380 |
Why?
|
| Down-Regulation | 7 | 2016 | 2074 | 0.380 |
Why?
|
| Biological Products | 3 | 2023 | 274 | 0.380 |
Why?
|
| Cell Cycle | 7 | 2017 | 2084 | 0.380 |
Why?
|
| Pathology, Molecular | 1 | 2011 | 128 | 0.380 |
Why?
|
| Animals | 42 | 2022 | 59536 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2023 | 1493 | 0.370 |
Why?
|
| Retreatment | 9 | 2019 | 452 | 0.370 |
Why?
|
| Terminology as Topic | 1 | 2013 | 414 | 0.370 |
Why?
|
| Isothiocyanates | 1 | 2010 | 44 | 0.370 |
Why?
|
| Gene Frequency | 5 | 2020 | 1163 | 0.370 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 121 | 0.370 |
Why?
|
| Ephrin-B2 | 1 | 2010 | 15 | 0.370 |
Why?
|
| Safety | 6 | 2019 | 465 | 0.360 |
Why?
|
| Radiotherapy | 3 | 2015 | 1824 | 0.360 |
Why?
|
| Rituximab | 15 | 2021 | 1528 | 0.360 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2013 | 622 | 0.360 |
Why?
|
| Receptor, EphB4 | 1 | 2010 | 27 | 0.360 |
Why?
|
| United States | 12 | 2022 | 15433 | 0.360 |
Why?
|
| Erythroblasts | 2 | 2020 | 24 | 0.360 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 2017 | 118 | 0.360 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 2138 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 2016 | 641 | 0.350 |
Why?
|
| RNA Splicing | 3 | 2023 | 370 | 0.350 |
Why?
|
| Ferritins | 4 | 2023 | 151 | 0.350 |
Why?
|
| Methylation | 5 | 2018 | 597 | 0.350 |
Why?
|
| Burkitt Lymphoma | 3 | 2022 | 335 | 0.350 |
Why?
|
| T-Lymphocytes | 6 | 2021 | 3869 | 0.350 |
Why?
|
| Time Factors | 29 | 2019 | 12926 | 0.350 |
Why?
|
| Gene Rearrangement | 7 | 2024 | 783 | 0.350 |
Why?
|
| Europe | 4 | 2020 | 649 | 0.350 |
Why?
|
| Sarcoma, Myeloid | 3 | 2021 | 95 | 0.350 |
Why?
|
| Pericardial Effusion | 1 | 2010 | 118 | 0.340 |
Why?
|
| Hemorrhage | 4 | 2023 | 712 | 0.340 |
Why?
|
| Phenotype | 8 | 2023 | 6295 | 0.340 |
Why?
|
| Patient Safety | 4 | 2021 | 649 | 0.340 |
Why?
|
| Allografts | 6 | 2022 | 650 | 0.340 |
Why?
|
| IMP Dehydrogenase | 2 | 2020 | 27 | 0.330 |
Why?
|
| Epoetin Alfa | 2 | 2023 | 27 | 0.330 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 3 | 2003 | 86 | 0.330 |
Why?
|
| TNF Receptor-Associated Factor 6 | 2 | 2020 | 37 | 0.330 |
Why?
|
| Cause of Death | 2 | 2020 | 752 | 0.330 |
Why?
|
| Mice | 27 | 2022 | 34495 | 0.330 |
Why?
|
| Sequence Analysis, DNA | 9 | 2021 | 2483 | 0.320 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2016 | 1217 | 0.320 |
Why?
|
| Models, Theoretical | 3 | 2018 | 785 | 0.320 |
Why?
|
| Cell Lineage | 7 | 2024 | 668 | 0.320 |
Why?
|
| Hepatic Veno-Occlusive Disease | 4 | 2023 | 122 | 0.320 |
Why?
|
| Transforming Growth Factor beta | 3 | 2019 | 1130 | 0.320 |
Why?
|
| Interleukin-8 | 3 | 2016 | 519 | 0.310 |
Why?
|
| Prednisone | 6 | 2021 | 984 | 0.310 |
Why?
|
| Blood Component Transfusion | 2 | 2019 | 89 | 0.310 |
Why?
|
| Sweet Syndrome | 2 | 2020 | 36 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 6 | 2008 | 72 | 0.310 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2007 | 54 | 0.310 |
Why?
|
| Receptors, Immunologic | 2 | 2020 | 309 | 0.310 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2019 | 255 | 0.300 |
Why?
|
| Receptors, KIR | 2 | 2018 | 62 | 0.300 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 2 | 2008 | 65 | 0.300 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 4 | 2020 | 310 | 0.300 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 251 | 0.300 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 2864 | 0.300 |
Why?
|
| Pilot Projects | 12 | 2019 | 2803 | 0.290 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2015 | 650 | 0.290 |
Why?
|
| L-Lactate Dehydrogenase | 5 | 2018 | 299 | 0.290 |
Why?
|
| Polyethylene Glycols | 4 | 2017 | 615 | 0.290 |
Why?
|
| DNA Repair | 5 | 2024 | 1872 | 0.290 |
Why?
|
| Referral and Consultation | 2 | 2016 | 899 | 0.290 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 509 | 0.290 |
Why?
|
| Genes, p53 | 6 | 2022 | 1090 | 0.290 |
Why?
|
| Immunotherapy | 10 | 2023 | 3341 | 0.290 |
Why?
|
| Dendritic Cells | 4 | 2022 | 1085 | 0.290 |
Why?
|
| Lymphoma | 4 | 2017 | 1467 | 0.290 |
Why?
|
| Pyridines | 6 | 2021 | 1244 | 0.280 |
Why?
|
| Area Under Curve | 5 | 2020 | 700 | 0.280 |
Why?
|
| Sex Factors | 6 | 2019 | 2139 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2013 | 4549 | 0.280 |
Why?
|
| Serine-Arginine Splicing Factors | 4 | 2023 | 88 | 0.280 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2018 | 598 | 0.280 |
Why?
|
| Recombinant Proteins | 9 | 2011 | 2927 | 0.280 |
Why?
|
| World Health Organization | 6 | 2020 | 316 | 0.280 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 3 | 2015 | 24 | 0.280 |
Why?
|
| Patients | 2 | 2020 | 245 | 0.280 |
Why?
|
| Child | 29 | 2021 | 29154 | 0.270 |
Why?
|
| Inflammation | 4 | 2023 | 2522 | 0.270 |
Why?
|
| Testicular Neoplasms | 2 | 2022 | 529 | 0.270 |
Why?
|
| Maintenance Chemotherapy | 4 | 2021 | 202 | 0.270 |
Why?
|
| Blood Cells | 2 | 2018 | 127 | 0.270 |
Why?
|
| Registries | 4 | 2023 | 2170 | 0.270 |
Why?
|
| Research Design | 7 | 2015 | 1544 | 0.270 |
Why?
|
| Cognition Disorders | 1 | 2011 | 786 | 0.260 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 1073 | 0.260 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2005 | 47 | 0.260 |
Why?
|
| RNA, Neoplasm | 6 | 2013 | 771 | 0.260 |
Why?
|
| Chromosome Banding | 4 | 2022 | 256 | 0.260 |
Why?
|
| Cell Differentiation | 8 | 2020 | 4078 | 0.260 |
Why?
|
| Nitriles | 6 | 2020 | 906 | 0.260 |
Why?
|
| Cerebral Hemorrhage | 1 | 2006 | 183 | 0.250 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2018 | 221 | 0.250 |
Why?
|
| Cytosine | 4 | 2012 | 141 | 0.250 |
Why?
|
| Genomics | 6 | 2022 | 2738 | 0.250 |
Why?
|
| Niacinamide | 6 | 2017 | 421 | 0.250 |
Why?
|
| Child, Preschool | 17 | 2021 | 16273 | 0.250 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 1165 | 0.250 |
Why?
|
| Trisomy | 4 | 2014 | 231 | 0.250 |
Why?
|
| Antigens, Neoplasm | 6 | 2021 | 1506 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2017 | 1039 | 0.240 |
Why?
|
| Harringtonines | 5 | 2017 | 92 | 0.240 |
Why?
|
| Morpholines | 2 | 2016 | 289 | 0.240 |
Why?
|
| Receptor, EphB2 | 2 | 2015 | 17 | 0.240 |
Why?
|
| Algorithms | 5 | 2021 | 3890 | 0.240 |
Why?
|
| Quality of Life | 8 | 2021 | 4532 | 0.240 |
Why?
|
| Asparaginase | 7 | 2021 | 184 | 0.240 |
Why?
|
| Pyrimidinones | 3 | 2019 | 314 | 0.240 |
Why?
|
| Transplantation Conditioning | 6 | 2022 | 2238 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2018 | 810 | 0.240 |
Why?
|
| Databases, Factual | 4 | 2021 | 2218 | 0.240 |
Why?
|
| Multigene Family | 3 | 2021 | 425 | 0.230 |
Why?
|
| Glycolysis | 3 | 2017 | 519 | 0.230 |
Why?
|
| Hematologic Diseases | 2 | 2020 | 242 | 0.230 |
Why?
|
| Receptors, Fc | 3 | 2012 | 69 | 0.230 |
Why?
|
| Point Mutation | 6 | 2019 | 769 | 0.230 |
Why?
|
| Dyspnea | 2 | 2023 | 416 | 0.220 |
Why?
|
| Thrombopoietin | 3 | 2012 | 77 | 0.220 |
Why?
|
| Feasibility Studies | 7 | 2020 | 2292 | 0.220 |
Why?
|
| Spliceosomes | 1 | 2023 | 75 | 0.220 |
Why?
|
| DNA Primers | 5 | 2013 | 1399 | 0.220 |
Why?
|
| History, 21st Century | 3 | 2018 | 441 | 0.220 |
Why?
|
| Nucleosides | 1 | 2022 | 60 | 0.220 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2023 | 106 | 0.220 |
Why?
|
| Base Sequence | 7 | 2015 | 4917 | 0.220 |
Why?
|
| Cyclosporine | 5 | 2012 | 278 | 0.220 |
Why?
|
| Treatment Failure | 12 | 2017 | 1391 | 0.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 12 | 2021 | 2232 | 0.210 |
Why?
|
| Tumor Protein p73 | 3 | 2008 | 105 | 0.210 |
Why?
|
| Antilymphocyte Serum | 3 | 2017 | 228 | 0.210 |
Why?
|
| Thrombosis | 2 | 2019 | 781 | 0.210 |
Why?
|
| Societies, Medical | 2 | 2018 | 1335 | 0.210 |
Why?
|
| Central Nervous System | 2 | 2022 | 436 | 0.210 |
Why?
|
| Leukapheresis | 2 | 2014 | 152 | 0.210 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 170 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 2594 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2010 | 528 | 0.210 |
Why?
|
| Disease Management | 4 | 2021 | 1052 | 0.210 |
Why?
|
| Jurkat Cells | 3 | 2010 | 311 | 0.210 |
Why?
|
| Nausea | 6 | 2015 | 525 | 0.200 |
Why?
|
| Pancytopenia | 2 | 2012 | 120 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 362 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2022 | 132 | 0.200 |
Why?
|
| Cell Survival | 7 | 2022 | 3045 | 0.200 |
Why?
|
| Leukemia, Lymphoid | 2 | 2017 | 276 | 0.200 |
Why?
|
| Drug Substitution | 2 | 2018 | 87 | 0.200 |
Why?
|
| Aging | 3 | 2009 | 1582 | 0.200 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2021 | 261 | 0.200 |
Why?
|
| Constipation | 2 | 2021 | 177 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2020 | 79 | 0.200 |
Why?
|
| Abnormal Karyotype | 2 | 2022 | 100 | 0.200 |
Why?
|
| Telomere Shortening | 1 | 2021 | 56 | 0.200 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 311 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 324 | 0.200 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2022 | 113 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 11 | 2014 | 864 | 0.200 |
Why?
|
| Complementarity Determining Regions | 1 | 2021 | 43 | 0.200 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2021 | 46 | 0.200 |
Why?
|
| Myeloid Cells | 4 | 2018 | 269 | 0.200 |
Why?
|
| Arthritis | 1 | 2022 | 139 | 0.200 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 53 | 0.200 |
Why?
|
| Bone Marrow Transplantation | 6 | 2014 | 1581 | 0.190 |
Why?
|
| Alleles | 5 | 2019 | 2437 | 0.190 |
Why?
|
| Cyclins | 1 | 2002 | 456 | 0.190 |
Why?
|
| Myosin Heavy Chains | 1 | 2021 | 128 | 0.190 |
Why?
|
| Injections, Subcutaneous | 6 | 2013 | 334 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 476 | 0.190 |
Why?
|
| Genetic Therapy | 1 | 2008 | 1616 | 0.190 |
Why?
|
| Fetal Blood | 2 | 2014 | 482 | 0.190 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2020 | 11 | 0.190 |
Why?
|
| Leukocytosis | 2 | 2014 | 112 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2014 | 134 | 0.190 |
Why?
|
| Arthralgia | 1 | 2021 | 89 | 0.190 |
Why?
|
| Gene Duplication | 3 | 2019 | 421 | 0.190 |
Why?
|
| Capsules | 1 | 2020 | 53 | 0.190 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 66 | 0.190 |
Why?
|
| Quinuclidines | 1 | 2021 | 48 | 0.190 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2021 | 141 | 0.190 |
Why?
|
| Genome, Human | 2 | 2009 | 1869 | 0.190 |
Why?
|
| Tablets | 1 | 2020 | 53 | 0.190 |
Why?
|
| Metaphase | 3 | 2017 | 107 | 0.190 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2017 | 503 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 330 | 0.190 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 160 | 0.190 |
Why?
|
| Diarrhea | 4 | 2018 | 686 | 0.190 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2020 | 69 | 0.190 |
Why?
|
| Polycythemia Vera | 4 | 2009 | 238 | 0.190 |
Why?
|
| Enzyme Activation | 3 | 2014 | 1764 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 59 | 0.180 |
Why?
|
| Patient Dropouts | 2 | 2019 | 88 | 0.180 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 254 | 0.180 |
Why?
|
| K562 Cells | 4 | 2014 | 338 | 0.180 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 58 | 0.180 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2019 | 39 | 0.180 |
Why?
|
| Siblings | 1 | 2021 | 285 | 0.180 |
Why?
|
| CREB-Binding Protein | 1 | 2020 | 86 | 0.180 |
Why?
|
| SEER Program | 2 | 2021 | 1000 | 0.180 |
Why?
|
| Texas | 10 | 2021 | 6311 | 0.180 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 2195 | 0.180 |
Why?
|
| Sequence Deletion | 5 | 2014 | 875 | 0.180 |
Why?
|
| Biological Availability | 2 | 2011 | 214 | 0.180 |
Why?
|
| Drugs, Generic | 1 | 2019 | 36 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 673 | 0.170 |
Why?
|
| Erythropoietin | 2 | 2011 | 205 | 0.170 |
Why?
|
| Fruit | 2 | 2013 | 294 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 582 | 0.170 |
Why?
|
| Proteomics | 3 | 2023 | 1380 | 0.170 |
Why?
|
| Liposomes | 6 | 2020 | 684 | 0.170 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 328 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 1121 | 0.170 |
Why?
|
| Cytogenetics | 3 | 2013 | 149 | 0.170 |
Why?
|
| Antigens, CD | 7 | 2021 | 1385 | 0.170 |
Why?
|
| Exanthema | 2 | 2019 | 211 | 0.170 |
Why?
|
| Sepsis | 2 | 2024 | 652 | 0.170 |
Why?
|
| Melatonin | 1 | 2019 | 46 | 0.170 |
Why?
|
| Prevalence | 4 | 2019 | 3260 | 0.170 |
Why?
|
| Vegetables | 2 | 2013 | 325 | 0.170 |
Why?
|
| Consolidation Chemotherapy | 5 | 2020 | 155 | 0.170 |
Why?
|
| Sample Size | 4 | 2019 | 202 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 2017 | 104 | 0.170 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 460 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2021 | 665 | 0.170 |
Why?
|
| Deoxycytidine | 3 | 2019 | 1353 | 0.170 |
Why?
|
| Protein Phosphatase 2C | 1 | 2018 | 75 | 0.160 |
Why?
|
| Pharmacokinetics | 2 | 2008 | 42 | 0.160 |
Why?
|
| Heterografts | 3 | 2020 | 733 | 0.160 |
Why?
|
| Diploidy | 1 | 2018 | 114 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 1146 | 0.160 |
Why?
|
| Drug Interactions | 2 | 2019 | 553 | 0.160 |
Why?
|
| Myeloid Progenitor Cells | 2 | 2016 | 49 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 65 | 0.160 |
Why?
|
| Body Weight | 1 | 2023 | 1293 | 0.160 |
Why?
|
| Quinolones | 3 | 2010 | 160 | 0.160 |
Why?
|
| Hypereosinophilic Syndrome | 3 | 2008 | 89 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2020 | 327 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2020 | 333 | 0.160 |
Why?
|
| Piperidines | 2 | 2019 | 1035 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2018 | 77 | 0.160 |
Why?
|
| Survival | 4 | 2018 | 177 | 0.160 |
Why?
|
| Mutation, Missense | 5 | 2021 | 1152 | 0.160 |
Why?
|
| Chromosomal Instability | 2 | 2013 | 233 | 0.160 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 52 | 0.160 |
Why?
|
| Mediastinal Neoplasms | 1 | 2022 | 423 | 0.160 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 52 | 0.160 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 475 | 0.160 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 92 | 0.160 |
Why?
|
| beta 2-Microglobulin | 2 | 2009 | 184 | 0.160 |
Why?
|
| Spasm | 1 | 2018 | 59 | 0.160 |
Why?
|
| Oxidation-Reduction | 3 | 2019 | 717 | 0.160 |
Why?
|
| Fever | 1 | 2021 | 497 | 0.160 |
Why?
|
| Vomiting | 4 | 2015 | 354 | 0.160 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 4143 | 0.150 |
Why?
|
| Nuclear Factor 45 Protein | 1 | 2017 | 12 | 0.150 |
Why?
|
| Single-Cell Analysis | 4 | 2021 | 470 | 0.150 |
Why?
|
| Blotting, Western | 7 | 2013 | 3536 | 0.150 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2017 | 19 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.150 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 1084 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 604 | 0.150 |
Why?
|
| International Cooperation | 5 | 2018 | 323 | 0.150 |
Why?
|
| Pyridones | 2 | 2019 | 348 | 0.150 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2016 | 13 | 0.150 |
Why?
|
| Blood Platelet Disorders | 1 | 2017 | 37 | 0.150 |
Why?
|
| Validation Studies as Topic | 3 | 2012 | 43 | 0.150 |
Why?
|
| Splicing Factor U2AF | 3 | 2023 | 48 | 0.150 |
Why?
|
| Interleukin-11 | 2 | 2008 | 37 | 0.150 |
Why?
|
| Thrombocythemia, Essential | 2 | 2009 | 162 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 643 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2018 | 242 | 0.150 |
Why?
|
| Mutation Rate | 4 | 2019 | 223 | 0.150 |
Why?
|
| Mercaptopurine | 4 | 2021 | 130 | 0.140 |
Why?
|
| Methyltransferases | 1 | 2018 | 148 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1763 | 0.140 |
Why?
|
| Tissue Distribution | 2 | 2015 | 875 | 0.140 |
Why?
|
| Telomere | 2 | 2021 | 505 | 0.140 |
Why?
|
| Protein Isoforms | 2 | 2016 | 842 | 0.140 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2016 | 24 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 169 | 0.140 |
Why?
|
| Histone Deacetylase 1 | 1 | 2016 | 62 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 2054 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 388 | 0.140 |
Why?
|
| Phosphorylation | 5 | 2017 | 4804 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 182 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2020 | 2588 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 417 | 0.140 |
Why?
|
| Cell Line | 7 | 2022 | 5114 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2018 | 587 | 0.140 |
Why?
|
| Immunoglobulin G | 2 | 2018 | 1021 | 0.140 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2017 | 161 | 0.140 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 2 | 2021 | 109 | 0.140 |
Why?
|
| Models, Molecular | 1 | 2021 | 1732 | 0.140 |
Why?
|
| Antibodies | 2 | 2023 | 838 | 0.140 |
Why?
|
| Amino Acid Substitution | 3 | 2013 | 644 | 0.140 |
Why?
|
| Receptors, Cytokine | 2 | 2016 | 176 | 0.140 |
Why?
|
| Sleep | 1 | 2019 | 413 | 0.130 |
Why?
|
| Mastocytosis, Systemic | 2 | 2008 | 110 | 0.130 |
Why?
|
| Serum Albumin | 2 | 2019 | 257 | 0.130 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 884 | 0.130 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 205 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 220 | 0.130 |
Why?
|
| Family | 2 | 2017 | 736 | 0.130 |
Why?
|
| Haploinsufficiency | 2 | 2015 | 294 | 0.130 |
Why?
|
| Farnesol | 1 | 2015 | 15 | 0.130 |
Why?
|
| Codon | 1 | 2015 | 241 | 0.130 |
Why?
|
| Antigens, CD20 | 4 | 2009 | 206 | 0.130 |
Why?
|
| Protein Kinases | 1 | 2019 | 874 | 0.130 |
Why?
|
| Thiosemicarbazones | 2 | 2006 | 23 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2021 | 1171 | 0.130 |
Why?
|
| Farnesyltranstransferase | 4 | 2010 | 122 | 0.130 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 32 | 0.130 |
Why?
|
| Transcription Factors | 5 | 2023 | 5270 | 0.130 |
Why?
|
| Salicylates | 1 | 2015 | 59 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2017 | 575 | 0.130 |
Why?
|
| DNA Damage | 3 | 2024 | 1954 | 0.130 |
Why?
|
| Valine | 1 | 2015 | 176 | 0.130 |
Why?
|
| Aurora Kinases | 1 | 2015 | 189 | 0.130 |
Why?
|
| Ondansetron | 1 | 2015 | 42 | 0.130 |
Why?
|
| Alkylating Agents | 2 | 2005 | 78 | 0.130 |
Why?
|
| raf Kinases | 1 | 2015 | 81 | 0.130 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2015 | 116 | 0.130 |
Why?
|
| Fibrosis | 3 | 2018 | 793 | 0.130 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 85 | 0.130 |
Why?
|
| Cell Communication | 2 | 2017 | 509 | 0.130 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2013 | 518 | 0.130 |
Why?
|
| STAT5 Transcription Factor | 2 | 2013 | 214 | 0.130 |
Why?
|
| Glutathione | 2 | 2019 | 368 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 848 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2014 | 408 | 0.120 |
Why?
|
| Cytotoxins | 1 | 2014 | 66 | 0.120 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2014 | 193 | 0.120 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2014 | 24 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 1487 | 0.120 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 85 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 445 | 0.120 |
Why?
|
| Skin Diseases | 1 | 2017 | 349 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 2508 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 717 | 0.120 |
Why?
|
| Cells, Cultured | 6 | 2020 | 5637 | 0.120 |
Why?
|
| U937 Cells | 2 | 2013 | 171 | 0.120 |
Why?
|
| Haplotypes | 1 | 2016 | 856 | 0.120 |
Why?
|
| Stem Cells | 1 | 2021 | 1213 | 0.120 |
Why?
|
| Peptides | 3 | 2013 | 1479 | 0.120 |
Why?
|
| Medical Futility | 1 | 2014 | 54 | 0.120 |
Why?
|
| Ubiquitination | 1 | 2016 | 575 | 0.120 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2012 | 65 | 0.120 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 60 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2014 | 135 | 0.120 |
Why?
|
| Acenaphthenes | 1 | 2013 | 6 | 0.120 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2013 | 17 | 0.120 |
Why?
|
| Dinucleoside Phosphates | 2 | 2003 | 19 | 0.120 |
Why?
|
| Glycoproteins | 5 | 2014 | 747 | 0.120 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2013 | 8 | 0.120 |
Why?
|
| Immunotoxins | 2 | 2012 | 117 | 0.120 |
Why?
|
| Cell Adhesion | 2 | 2017 | 1008 | 0.120 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 184 | 0.120 |
Why?
|
| Necrosis | 1 | 2015 | 580 | 0.120 |
Why?
|
| Leukemia, Experimental | 2 | 2017 | 78 | 0.120 |
Why?
|
| DNA | 4 | 2013 | 2693 | 0.120 |
Why?
|
| Carbazoles | 2 | 2014 | 87 | 0.120 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 905 | 0.120 |
Why?
|
| Fabaceae | 1 | 2013 | 26 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 1999 | 462 | 0.120 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2013 | 30 | 0.120 |
Why?
|
| Ribonucleotides | 1 | 2013 | 52 | 0.120 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 1058 | 0.110 |
Why?
|
| Receptor, Notch3 | 1 | 2013 | 31 | 0.110 |
Why?
|
| Amifostine | 2 | 2004 | 97 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 78 | 0.110 |
Why?
|
| Gene Order | 1 | 2013 | 111 | 0.110 |
Why?
|
| Meat | 1 | 2013 | 87 | 0.110 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2013 | 85 | 0.110 |
Why?
|
| Erythroid Cells | 1 | 2013 | 49 | 0.110 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 6089 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2018 | 710 | 0.110 |
Why?
|
| Reactive Oxygen Species | 3 | 2019 | 987 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2013 | 87 | 0.110 |
Why?
|
| Chromatin | 1 | 2018 | 942 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2018 | 5710 | 0.110 |
Why?
|
| Jagged-1 Protein | 1 | 2013 | 101 | 0.110 |
Why?
|
| Bone Marrow Diseases | 2 | 2012 | 177 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 355 | 0.110 |
Why?
|
| Skin Neoplasms | 2 | 2022 | 4654 | 0.110 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 2012 | 21 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2012 | 23 | 0.110 |
Why?
|
| Infant | 8 | 2022 | 13310 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.110 |
Why?
|
| Transcription, Genetic | 5 | 2013 | 3154 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2015 | 584 | 0.110 |
Why?
|
| Drug Delivery Systems | 3 | 2011 | 669 | 0.110 |
Why?
|
| Carcinogenesis | 2 | 2022 | 1026 | 0.110 |
Why?
|
| Genetic Testing | 2 | 2018 | 1589 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1945 | 0.110 |
Why?
|
| Lymphocytes | 2 | 2015 | 1234 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 636 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2004 | 272 | 0.100 |
Why?
|
| Mitochondria | 3 | 2017 | 1282 | 0.100 |
Why?
|
| HEK293 Cells | 4 | 2019 | 1489 | 0.100 |
Why?
|
| Solvents | 1 | 2012 | 66 | 0.100 |
Why?
|
| Camptothecin | 3 | 2004 | 517 | 0.100 |
Why?
|
| Injections, Intravenous | 5 | 2015 | 573 | 0.100 |
Why?
|
| Colony-Stimulating Factors | 1 | 2011 | 82 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 6 | 2011 | 2992 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1664 | 0.100 |
Why?
|
| Thiadiazoles | 1 | 2011 | 47 | 0.100 |
Why?
|
| Arthritis, Infectious | 1 | 2012 | 68 | 0.100 |
Why?
|
| Intelligence Tests | 1 | 2011 | 88 | 0.100 |
Why?
|
| Nomograms | 3 | 2011 | 313 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2007 | 852 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2022 | 1586 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2014 | 333 | 0.100 |
Why?
|
| Antimitotic Agents | 1 | 2011 | 8 | 0.100 |
Why?
|
| Anxiety | 1 | 2019 | 1179 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2012 | 193 | 0.100 |
Why?
|
| Blotting, Southern | 3 | 2010 | 406 | 0.100 |
Why?
|
| Cisplatin | 1 | 2018 | 2432 | 0.100 |
Why?
|
| Anti-Infective Agents | 2 | 2008 | 446 | 0.100 |
Why?
|
| Immunization, Passive | 2 | 2003 | 172 | 0.100 |
Why?
|
| Chromosomes, Human, Y | 1 | 2011 | 53 | 0.100 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 216 | 0.100 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2010 | 37 | 0.100 |
Why?
|
| Exercise | 1 | 2019 | 1183 | 0.100 |
Why?
|
| Biological Assay | 1 | 2012 | 177 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2011 | 64 | 0.100 |
Why?
|
| Candida | 1 | 2012 | 164 | 0.100 |
Why?
|
| Down Syndrome | 1 | 2013 | 226 | 0.090 |
Why?
|
| Hydroxyurea | 2 | 2022 | 204 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 4233 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 3 | 2022 | 2314 | 0.090 |
Why?
|
| Cyclin H | 1 | 2010 | 2 | 0.090 |
Why?
|
| Fungemia | 3 | 2008 | 116 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 545 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2016 | 2022 | 0.090 |
Why?
|
| Ephrins | 1 | 2010 | 9 | 0.090 |
Why?
|
| Pain | 1 | 2019 | 1658 | 0.090 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2010 | 69 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2003 | 2278 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 895 | 0.090 |
Why?
|
| Blood Cell Count | 2 | 2008 | 225 | 0.090 |
Why?
|
| Receptors, Eph Family | 1 | 2010 | 19 | 0.090 |
Why?
|
| Splenomegaly | 3 | 2017 | 158 | 0.090 |
Why?
|
| Oxidative Phosphorylation | 1 | 2011 | 253 | 0.090 |
Why?
|
| Mucormycosis | 1 | 2011 | 108 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 11538 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2012 | 244 | 0.090 |
Why?
|
| Breast Neoplasms | 5 | 2015 | 15694 | 0.090 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2010 | 116 | 0.090 |
Why?
|
| Oncogenes | 1 | 2013 | 673 | 0.090 |
Why?
|
| Candidiasis | 1 | 2012 | 262 | 0.090 |
Why?
|
| Trans-Activators | 2 | 2013 | 1555 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 252 | 0.090 |
Why?
|
| Short Interspersed Nucleotide Elements | 1 | 2009 | 27 | 0.090 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 146 | 0.090 |
Why?
|
| RNA, Long Noncoding | 2 | 2013 | 598 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2014 | 1038 | 0.090 |
Why?
|
| Time | 2 | 2020 | 178 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 213 | 0.090 |
Why?
|
| Homeodomain Proteins | 4 | 2022 | 1143 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 806 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 4744 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 778 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 1997 | 1959 | 0.090 |
Why?
|
| Ascites | 1 | 2010 | 198 | 0.090 |
Why?
|
| Biopsy | 4 | 2018 | 3443 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2010 | 392 | 0.090 |
Why?
|
| Endonucleases | 1 | 2010 | 178 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 5687 | 0.090 |
Why?
|
| Filgrastim | 2 | 2006 | 191 | 0.090 |
Why?
|
| RNA, Untranslated | 2 | 2008 | 237 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 266 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 1439 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 5 | 2022 | 2403 | 0.080 |
Why?
|
| Standard of Care | 1 | 2010 | 243 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2009 | 166 | 0.080 |
Why?
|
| Cell Death | 1 | 2011 | 671 | 0.080 |
Why?
|
| Depression | 1 | 2019 | 1715 | 0.080 |
Why?
|
| Uniparental Disomy | 1 | 2009 | 66 | 0.080 |
Why?
|
| Survivors | 1 | 2014 | 1031 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 475 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2009 | 207 | 0.080 |
Why?
|
| Cooking | 1 | 2008 | 66 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 854 | 0.080 |
Why?
|
| Pleural Effusion | 1 | 2010 | 201 | 0.080 |
Why?
|
| Predictive Value of Tests | 6 | 2016 | 4892 | 0.080 |
Why?
|
| Fatal Outcome | 3 | 2012 | 829 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2020 | 1819 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2014 | 2316 | 0.080 |
Why?
|
| Benzothiazoles | 2 | 2021 | 94 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 2 | 2006 | 259 | 0.080 |
Why?
|
| Genes, abl | 3 | 2019 | 110 | 0.080 |
Why?
|
| Cell Division | 2 | 2010 | 2489 | 0.080 |
Why?
|
| Cerebellar Neoplasms | 1 | 2012 | 434 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-hck | 1 | 2007 | 4 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 2013 | 808 | 0.080 |
Why?
|
| Drug Tolerance | 1 | 2007 | 114 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2013 | 479 | 0.080 |
Why?
|
| Logistic Models | 4 | 2017 | 3441 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2009 | 652 | 0.080 |
Why?
|
| Protein Phosphatase 1 | 1 | 2007 | 79 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2016 | 907 | 0.070 |
Why?
|
| Reticulin | 2 | 2018 | 22 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 347 | 0.070 |
Why?
|
| Chromosome Disorders | 1 | 2010 | 417 | 0.070 |
Why?
|
| Drug Evaluation | 2 | 2020 | 425 | 0.070 |
Why?
|
| Staurosporine | 2 | 2019 | 143 | 0.070 |
Why?
|
| Meninges | 1 | 2007 | 47 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2010 | 321 | 0.070 |
Why?
|
| Antioxidants | 1 | 2010 | 507 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 223 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2012 | 540 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 566 | 0.070 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2004 | 75 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1283 | 0.070 |
Why?
|
| Lymphocyte Count | 2 | 2018 | 486 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2022 | 3821 | 0.070 |
Why?
|
| Dioxolanes | 2 | 2003 | 41 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2003 | 134 | 0.070 |
Why?
|
| Transplantation, Autologous | 2 | 2023 | 1914 | 0.070 |
Why?
|
| Deoxyglucose | 2 | 2017 | 115 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2019 | 588 | 0.070 |
Why?
|
| Datasets as Topic | 2 | 2018 | 181 | 0.070 |
Why?
|
| Smoking | 2 | 2014 | 2440 | 0.070 |
Why?
|
| Outpatients | 1 | 2009 | 462 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 4314 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2022 | 1230 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2007 | 869 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 1033 | 0.070 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2016 | 76 | 0.070 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2005 | 51 | 0.070 |
Why?
|
| Splenic Neoplasms | 1 | 2006 | 119 | 0.070 |
Why?
|
| Bayes Theorem | 3 | 2019 | 1021 | 0.070 |
Why?
|
| Biosensing Techniques | 1 | 2006 | 75 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2011 | 686 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 538 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2004 | 1533 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 1390 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 1450 | 0.060 |
Why?
|
| Injections, Spinal | 2 | 2007 | 257 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 87 | 0.060 |
Why?
|
| Triazoles | 1 | 2009 | 617 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2006 | 515 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 482 | 0.060 |
Why?
|
| Gene Deletion | 3 | 2017 | 1442 | 0.060 |
Why?
|
| Cell Movement | 1 | 2012 | 2466 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 7789 | 0.060 |
Why?
|
| Interferons | 2 | 2021 | 291 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2007 | 478 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 7548 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 87 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2003 | 51 | 0.060 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 502 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2005 | 170 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 672 | 0.060 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2023 | 59 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 598 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2006 | 196 | 0.060 |
Why?
|
| Consensus | 2 | 2023 | 978 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 702 | 0.060 |
Why?
|
| Liver Diseases | 2 | 2012 | 574 | 0.060 |
Why?
|
| Sulfites | 1 | 2002 | 44 | 0.060 |
Why?
|
| Mitoxantrone | 1 | 2003 | 216 | 0.060 |
Why?
|
| Thioguanine | 2 | 2014 | 68 | 0.060 |
Why?
|
| Cholagogues and Choleretics | 1 | 2002 | 33 | 0.060 |
Why?
|
| CD52 Antigen | 3 | 2009 | 46 | 0.060 |
Why?
|
| Erythroid Precursor Cells | 1 | 2022 | 61 | 0.050 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2002 | 51 | 0.050 |
Why?
|
| Iron | 2 | 2020 | 376 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2004 | 289 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 6942 | 0.050 |
Why?
|
| Pedigree | 2 | 2017 | 1890 | 0.050 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2002 | 13 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 1077 | 0.050 |
Why?
|
| Income | 1 | 2023 | 222 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 6009 | 0.050 |
Why?
|
| Forecasting | 1 | 2005 | 694 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 75 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2004 | 362 | 0.050 |
Why?
|
| Etoposide | 2 | 2017 | 870 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 275 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2002 | 355 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2265 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 803 | 0.050 |
Why?
|
| Solubility | 1 | 2022 | 242 | 0.050 |
Why?
|
| Furans | 2 | 2014 | 104 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2005 | 473 | 0.050 |
Why?
|
| Cell Self Renewal | 1 | 2021 | 62 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 91 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2022 | 164 | 0.050 |
Why?
|
| Hematologic Tests | 2 | 2017 | 82 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2018 | 409 | 0.050 |
Why?
|
| Megakaryocytes | 1 | 2021 | 104 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 434 | 0.050 |
Why?
|
| Selection Bias | 1 | 2001 | 50 | 0.050 |
Why?
|
| Kidney | 1 | 2010 | 2146 | 0.050 |
Why?
|
| Pyrazines | 1 | 2004 | 495 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 27 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 132 | 0.050 |
Why?
|
| Oncogene Fusion | 1 | 2021 | 63 | 0.050 |
Why?
|
| Sesquiterpenes | 1 | 2001 | 68 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1070 | 0.050 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2020 | 16 | 0.050 |
Why?
|
| Skin | 2 | 2017 | 1259 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 1688 | 0.050 |
Why?
|
| Triazines | 1 | 2021 | 117 | 0.050 |
Why?
|
| High-Throughput Screening Assays | 1 | 2022 | 216 | 0.050 |
Why?
|
| Infusions, Subcutaneous | 1 | 2020 | 13 | 0.050 |
Why?
|
| Probability | 3 | 2010 | 866 | 0.050 |
Why?
|
| Small Molecule Libraries | 1 | 2022 | 169 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 143 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2020 | 72 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 834 | 0.050 |
Why?
|
| Survivorship | 1 | 2020 | 109 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 179 | 0.050 |
Why?
|
| Genotype | 3 | 2014 | 4109 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2019 | 49 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2001 | 248 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2134 | 0.040 |
Why?
|
| Autoantigens | 1 | 2021 | 234 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 266 | 0.040 |
Why?
|
| Transfusion Reaction | 1 | 2020 | 102 | 0.040 |
Why?
|
| Prodrugs | 1 | 2021 | 217 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 189 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2019 | 19 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 543 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 577 | 0.040 |
Why?
|
| beta-Thalassemia | 1 | 1999 | 17 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2000 | 181 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2019 | 69 | 0.040 |
Why?
|
| NADP | 1 | 2019 | 96 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 524 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2021 | 354 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2019 | 67 | 0.040 |
Why?
|
| Pregnancy | 2 | 2023 | 7573 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 81 | 0.040 |
Why?
|
| Bilirubin | 2 | 2014 | 221 | 0.040 |
Why?
|
| Hematologic Agents | 1 | 2018 | 13 | 0.040 |
Why?
|
| Anthracyclines | 2 | 2010 | 331 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2019 | 289 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2021 | 362 | 0.040 |
Why?
|
| Germ Cells | 1 | 2020 | 335 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 314 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 1443 | 0.040 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 333 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 29 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2019 | 137 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 339 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 166 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 984 | 0.040 |
Why?
|
| Mastectomy, Radical | 1 | 1997 | 39 | 0.040 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2017 | 36 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2018 | 93 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2018 | 339 | 0.040 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 1946 | 0.040 |
Why?
|
| Naphthyridines | 1 | 2017 | 41 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 201 | 0.040 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2017 | 12 | 0.040 |
Why?
|
| Heterogeneous Nuclear Ribonucleoprotein A1 | 1 | 2016 | 8 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2022 | 2063 | 0.040 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2016 | 42 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2014 | 1869 | 0.040 |
Why?
|
| Hexokinase | 1 | 2017 | 36 | 0.040 |
Why?
|
| Propionates | 1 | 2017 | 71 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 671 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 227 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 761 | 0.040 |
Why?
|
| Glucocorticoids | 2 | 2012 | 629 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 834 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 769 | 0.040 |
Why?
|
| Transglutaminases | 1 | 1997 | 99 | 0.040 |
Why?
|
| Orchiectomy | 1 | 1997 | 214 | 0.040 |
Why?
|
| Guanine | 1 | 2017 | 151 | 0.040 |
Why?
|
| Pyruvates | 1 | 2016 | 28 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2009 | 223 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2018 | 267 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2020 | 1113 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2017 | 185 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 275 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 340 | 0.030 |
Why?
|
| Leukopenia | 1 | 2016 | 151 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 995 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 91 | 0.030 |
Why?
|
| Receptor, EphA1 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2015 | 42 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 485 | 0.030 |
Why?
|
| Proteins | 1 | 2004 | 1963 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 1997 | 267 | 0.030 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2015 | 38 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1997 | 321 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 115 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2016 | 188 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 478 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 259 | 0.030 |
Why?
|
| Kinetics | 1 | 2018 | 2049 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 178 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1997 | 330 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 750 | 0.030 |
Why?
|
| Age of Onset | 2 | 2010 | 827 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2016 | 263 | 0.030 |
Why?
|
| Metagenome | 1 | 2016 | 176 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 275 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 245 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2015 | 123 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 508 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 571 | 0.030 |
Why?
|
| Transaminases | 1 | 2014 | 76 | 0.030 |
Why?
|
| Models, Chemical | 2 | 2005 | 186 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2014 | 155 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2014 | 88 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 257 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 270 | 0.030 |
Why?
|
| Alemtuzumab | 2 | 2006 | 198 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2015 | 218 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 490 | 0.030 |
Why?
|
| Seafood | 1 | 2013 | 9 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 2 | 2004 | 231 | 0.030 |
Why?
|
| Receptor, EphA5 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2016 | 380 | 0.030 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2013 | 63 | 0.030 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2013 | 31 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 42 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 1323 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2016 | 829 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 840 | 0.030 |
Why?
|
| Organophosphates | 1 | 2013 | 41 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 3 | 2006 | 1547 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2017 | 825 | 0.030 |
Why?
|
| Rats | 1 | 2022 | 6086 | 0.030 |
Why?
|
| Mouth Mucosa | 2 | 2004 | 216 | 0.030 |
Why?
|
| Host Cell Factor C1 | 1 | 2012 | 14 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 611 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 208 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2003 | 212 | 0.030 |
Why?
|
| Glucose | 1 | 2019 | 1248 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2013 | 122 | 0.030 |
Why?
|
| Ephrin-B1 | 1 | 2012 | 9 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 175 | 0.030 |
Why?
|
| Synovial Fluid | 1 | 2012 | 27 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 415 | 0.030 |
Why?
|
| Endothelial Growth Factors | 2 | 2003 | 197 | 0.030 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2012 | 46 | 0.030 |
Why?
|
| Chondrocalcinosis | 1 | 2012 | 19 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 7222 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1997 | 891 | 0.030 |
Why?
|
| International Agencies | 1 | 2012 | 107 | 0.030 |
Why?
|
| Topotecan | 2 | 2003 | 239 | 0.030 |
Why?
|
| Lymphokines | 2 | 2003 | 272 | 0.030 |
Why?
|
| Color | 1 | 2012 | 66 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 1183 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2012 | 171 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2014 | 176 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 756 | 0.030 |
Why?
|
| Drug Resistance, Fungal | 1 | 2012 | 92 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2013 | 264 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2012 | 153 | 0.030 |
Why?
|
| Cyclosporins | 1 | 2011 | 112 | 0.030 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2011 | 19 | 0.030 |
Why?
|
| Perception | 1 | 2014 | 350 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2011 | 49 | 0.030 |
Why?
|
| Stomatitis | 2 | 2003 | 183 | 0.030 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2011 | 102 | 0.030 |
Why?
|
| Bacteremia | 2 | 2008 | 689 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2011 | 62 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 256 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 133 | 0.020 |
Why?
|
| Knee Joint | 1 | 2012 | 161 | 0.020 |
Why?
|
| Life Support Care | 1 | 2011 | 50 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 4975 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8223 | 0.020 |
Why?
|
| Colonic Diseases | 1 | 2011 | 71 | 0.020 |
Why?
|
| Anemia, Macrocytic | 1 | 2010 | 12 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 359 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 945 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Doxycycline | 1 | 2011 | 178 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2011 | 247 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 2011 | 124 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 406 | 0.020 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 430 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2012 | 306 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1678 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 938 | 0.020 |
Why?
|
| Exome | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 3438 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2004 | 2307 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 64 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 254 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2009 | 264 | 0.020 |
Why?
|
| Alu Elements | 1 | 2009 | 88 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 157 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 195 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 748 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2009 | 92 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 2173 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2009 | 164 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 745 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2009 | 220 | 0.020 |
Why?
|
| Fever of Unknown Origin | 1 | 2008 | 63 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 923 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 622 | 0.020 |
Why?
|
| Mastectomy | 1 | 2014 | 1534 | 0.020 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2008 | 115 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 957 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2007 | 72 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 7551 | 0.020 |
Why?
|
| Polyradiculopathy | 1 | 2007 | 13 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 602 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 78 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2007 | 104 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 717 | 0.020 |
Why?
|
| Basophils | 1 | 2006 | 38 | 0.020 |
Why?
|
| Cinnamates | 1 | 2006 | 27 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2008 | 315 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2007 | 348 | 0.020 |
Why?
|
| Meningitis | 1 | 2007 | 112 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2006 | 33 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2012 | 834 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2006 | 133 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1489 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 2216 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 57 | 0.020 |
Why?
|
| Papilledema | 1 | 2007 | 85 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 78 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 69 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 55 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2005 | 110 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2008 | 574 | 0.020 |
Why?
|
| Splenectomy | 1 | 2006 | 158 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 1440 | 0.020 |
Why?
|
| Encephalitis | 1 | 2007 | 143 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 980 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 157 | 0.020 |
Why?
|
| Physicians | 1 | 2014 | 882 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 1328 | 0.020 |
Why?
|
| Tubulin | 1 | 2005 | 169 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 188 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2008 | 702 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2004 | 66 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 435 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 1351 | 0.020 |
Why?
|
| CD13 Antigens | 1 | 2004 | 36 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 931 | 0.020 |
Why?
|
| Microtubules | 1 | 2005 | 270 | 0.020 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2003 | 24 | 0.020 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2003 | 21 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 2944 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2003 | 83 | 0.010 |
Why?
|
| Genes, APC | 1 | 2003 | 70 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2011 | 4307 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 4971 | 0.010 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 62 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 507 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2003 | 191 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 2003 | 78 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5112 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2003 | 153 | 0.010 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 231 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2004 | 365 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 227 | 0.010 |
Why?
|
| Intestinal Neoplasms | 1 | 2003 | 189 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2004 | 255 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 195 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 1099 | 0.010 |
Why?
|
| Obesity | 1 | 2014 | 2884 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 589 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 989 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2005 | 607 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1538 | 0.010 |
Why?
|
| Cytokines | 1 | 2009 | 2809 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 889 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2005 | 1048 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2003 | 462 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1997 | 115 | 0.010 |
Why?
|
| Myosins | 1 | 1997 | 96 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1997 | 201 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2009 | 2341 | 0.010 |
Why?
|
| Cytosol | 1 | 1997 | 238 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1997 | 682 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2007 | 2967 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1997 | 886 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1997 | 663 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1997 | 769 | 0.010 |
Why?
|